[go: up one dir, main page]

CU20100264A7 - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables - Google Patents

Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables

Info

Publication number
CU20100264A7
CU20100264A7 CU2010000264A CU20100264A CU20100264A7 CU 20100264 A7 CU20100264 A7 CU 20100264A7 CU 2010000264 A CU2010000264 A CU 2010000264A CU 20100264 A CU20100264 A CU 20100264A CU 20100264 A7 CU20100264 A7 CU 20100264A7
Authority
CU
Cuba
Prior art keywords
vegf
mutagenesis
growth factor
human
variable regions
Prior art date
Application number
CU2010000264A
Other languages
English (en)
Other versions
CU23895B1 (es
Inventor
Sanchez Lincidio Perez
Merino Amaury Pupo
Pozo Yasmiana Munoz
Ordas Humberto Lamdan
Avila Marta Ayala
Dorantes Gertrudis Rojas
Cowley Jorge Victor Gavilondo
Original Assignee
Biorec Sa
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorec Sa, Ct Ingenieria Genetica Biotech filed Critical Biorec Sa
Priority to CU20100264A priority Critical patent/CU23895B1/es
Priority to CA2823233A priority patent/CA2823233C/en
Priority to AU2011352474A priority patent/AU2011352474B2/en
Priority to BR112013016684A priority patent/BR112013016684A2/pt
Priority to KR1020137019847A priority patent/KR101896108B1/ko
Priority to PCT/CU2011/000009 priority patent/WO2012089176A1/es
Priority to RU2013134983/10A priority patent/RU2557309C2/ru
Priority to EP11820879.2A priority patent/EP2662388B1/en
Priority to ES11820879.2T priority patent/ES2687183T3/es
Priority to JP2013546584A priority patent/JP6082698B2/ja
Priority to MYPI2013701133A priority patent/MY166550A/en
Priority to CN201180066879.4A priority patent/CN103370336B/zh
Priority to US13/976,060 priority patent/US9505830B2/en
Priority to MX2013007645A priority patent/MX344915B/es
Priority to TW100148878A priority patent/TWI555757B/zh
Priority to ARP110104967A priority patent/AR084618A1/es
Priority to UY0001033844A priority patent/UY33844A/es
Publication of CU20100264A7 publication Critical patent/CU20100264A7/es
Publication of CU23895B1 publication Critical patent/CU23895B1/es
Priority to ZA2013/05031A priority patent/ZA201305031B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención revela anticuerpos recombinantes humanos que reconocen el Factor de Crecimiento del Endotelio Vascular-A (VEGF-A) humano, bloquean su interacción con el receptor VEGFR2, e interfieren con sus efectos proliferativos in vitro y pro-angiogénicos in vivo. Estos anticuerpos identifican un epitope en el VEGF-A humano diferente a cualquier otro reportado antes y se obtuvieron combinando una misma región variable de cadena ligera de inmunoglobulinas, con otras tres de cadena pesada. Los anticuerpos se obtuvieron mediante mutagénesis de regiones variables de inmunoglobulinas humanas, y pueden emplearse para la inmunoterapia de entidades patológicas cuyo curso esté asociado al aumento de la vasculatura, tales como la degeneración macular asociada a la edad, el cáncer y otras.
CU20100264A 2010-12-28 2010-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables CU23895B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU20100264A CU23895B1 (es) 2010-12-28 2010-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables
JP2013546584A JP6082698B2 (ja) 2010-12-28 2011-12-26 可変領域の突然変異誘発によって得られる血管内皮増殖因子（ｖｅｇｆ）に対する組換え抗体
MYPI2013701133A MY166550A (en) 2010-12-28 2011-12-26 Recombinant antibodies against the vascular endothelium growth factor (vegf) obtained by variable region mutagenesis
BR112013016684A BR112013016684A2 (pt) 2010-12-28 2011-12-26 anticorpos recombinantes, vetores que codificam para os anticorpos recombinantes, composições farmacêuticas e uso dos anticorpos recombinantes
KR1020137019847A KR101896108B1 (ko) 2010-12-28 2011-12-26 가변부의 돌연변이에 의하여 제조한 맥관 내피 성장 인자(vegf)에 대한 재조합 항체
PCT/CU2011/000009 WO2012089176A1 (es) 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables
RU2013134983/10A RU2557309C2 (ru) 2010-12-28 2011-12-26 Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области
EP11820879.2A EP2662388B1 (en) 2010-12-28 2011-12-26 Recombinant antibodies to the vascular endothelial growth factor (vegf) which are obtained by means of mutagenesis of variable regions
ES11820879.2T ES2687183T3 (es) 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento endotelial vascular (VEGF) que se obtienen mediante mutagénesis de regiones variables
CA2823233A CA2823233C (en) 2010-12-28 2011-12-26 Recombinant antibodies against the vascular endothelium growth factor (vegf) obtained by variable region mutagenesis
AU2011352474A AU2011352474B2 (en) 2010-12-28 2011-12-26 Recombinant antibodies to the vascular endothelial growth factor (VEGF-A) which are obtained by means of mutagenesis of variable regions
CN201180066879.4A CN103370336B (zh) 2010-12-28 2011-12-26 通过可变区诱变获得的抗血管内皮生长因子(vegf)重组抗体
US13/976,060 US9505830B2 (en) 2010-12-28 2011-12-26 Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions
MX2013007645A MX344915B (es) 2010-12-28 2011-12-26 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables.
TW100148878A TWI555757B (zh) 2010-12-28 2011-12-27 藉變異區突變獲得的抗血管內皮生長因子（ｖｅｇｆ）之重組抗體
ARP110104967A AR084618A1 (es) 2010-12-28 2011-12-27 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagenesis de regiones variables
UY0001033844A UY33844A (es) 2010-12-28 2011-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)obtenidos mediante mutagenesis de regiones variables
ZA2013/05031A ZA201305031B (en) 2010-12-28 2013-07-04 Recombinant antibodies to the vascular endothelial growth factor (vegf) which are obtained by means of matagenesis of variable regions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20100264A CU23895B1 (es) 2010-12-28 2010-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables

Publications (2)

Publication Number Publication Date
CU20100264A7 true CU20100264A7 (es) 2012-07-31
CU23895B1 CU23895B1 (es) 2013-05-31

Family

ID=45768110

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100264A CU23895B1 (es) 2010-12-28 2010-12-28 Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables

Country Status (18)

Country Link
US (1) US9505830B2 (es)
EP (1) EP2662388B1 (es)
JP (1) JP6082698B2 (es)
KR (1) KR101896108B1 (es)
CN (1) CN103370336B (es)
AR (1) AR084618A1 (es)
AU (1) AU2011352474B2 (es)
BR (1) BR112013016684A2 (es)
CA (1) CA2823233C (es)
CU (1) CU23895B1 (es)
ES (1) ES2687183T3 (es)
MX (1) MX344915B (es)
MY (1) MY166550A (es)
RU (1) RU2557309C2 (es)
TW (1) TWI555757B (es)
UY (1) UY33844A (es)
WO (1) WO2012089176A1 (es)
ZA (1) ZA201305031B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CL2014002941A1 (es) * 2014-10-30 2015-04-06 Univ Concepcion Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf)
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
WO2019129677A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
EP3898669A1 (en) * 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CU24770B1 (es) 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CU23636A1 (es) * 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
WO2008105248A1 (ja) 2007-02-27 2008-09-04 Nikon Corporation ズームレンズと、これを有する光学装置
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CU23895B1 (es) 2013-05-31
KR101896108B1 (ko) 2018-09-10
UY33844A (es) 2012-07-31
CN103370336A (zh) 2013-10-23
AU2011352474A1 (en) 2013-08-15
MX2013007645A (es) 2013-12-02
EP2662388A1 (en) 2013-11-13
KR20140019316A (ko) 2014-02-14
CA2823233C (en) 2020-06-09
JP2014504498A (ja) 2014-02-24
RU2557309C2 (ru) 2015-07-20
TW201305203A (zh) 2013-02-01
TWI555757B (zh) 2016-11-01
RU2013134983A (ru) 2015-02-10
US20140086829A1 (en) 2014-03-27
JP6082698B2 (ja) 2017-02-15
ES2687183T3 (es) 2018-10-24
WO2012089176A1 (es) 2012-07-05
BR112013016684A2 (pt) 2017-06-06
MX344915B (es) 2017-01-10
AU2011352474B2 (en) 2017-02-16
CA2823233A1 (en) 2012-07-05
CN103370336B (zh) 2015-11-25
MY166550A (en) 2018-07-16
ZA201305031B (en) 2014-03-26
US9505830B2 (en) 2016-11-29
EP2662388B1 (en) 2018-08-22
AR084618A1 (es) 2013-05-29

Similar Documents

Publication Publication Date Title
UY33844A (es) Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)obtenidos mediante mutagenesis de regiones variables
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
MX395028B (es) Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
PE20161390A1 (es) Anticuerpos multiespecificos
CO2017000510A2 (es) Constructos de car
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
CU24437B1 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
PE20181515A1 (es) Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX372754B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
PE20160123A1 (es) Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX378108B (es) Anticuerpos anti-met y composiciones.
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer

Legal Events

Date Code Title Description
FG Grant of patent